Patient disposition
| . | Patients (N = 25) . |
|---|---|
| ITT population, n | 25 |
| mITT population, n | 25 |
| Patient status at end of infusion 1 interventional phase, n (%)* | 25 (100) |
| Disease progression | 22 (88) |
| Did not progress† | 3 (12) |
| Patient status at end of infusion 2 interventional phase (for patients with second infusion), n (%)* | 4 (16) |
| Disease progression‡ | 4 (16) |
| . | Patients (N = 25) . |
|---|---|
| ITT population, n | 25 |
| mITT population, n | 25 |
| Patient status at end of infusion 1 interventional phase, n (%)* | 25 (100) |
| Disease progression | 22 (88) |
| Did not progress† | 3 (12) |
| Patient status at end of infusion 2 interventional phase (for patients with second infusion), n (%)* | 4 (16) |
| Disease progression‡ | 4 (16) |
Patients completed the study if they discontinued because of disease progression or death after their last T-cell infusion, or if they were progression-free at the time of study completion (at Sponsor discretion) and moved into long-term follow-up. ITT population: all patients who were enrolled in the trial. mITT population: all patients in the ITT population who received ≥ 1 T-cell infusion.
Denominator for percentages is based on the ITT population.
Did not progress by the time of the primary analysis; participation was terminated by the study sponsor.
One patient progressed before withdrawing consent.